·111·实用心脑肺血管病杂志2023年9月第31卷第9期投稿网址：http://www.syxnf.net·新进展·黄芪甲苷抗心力衰竭患者缺血缺氧性心肌损伤的机制研究进展关静1，黄凡克1，周伊璐1，李冰清1，陈余文1，王悦1，孙培媛1，吕建峰2【摘要】黄芪甲苷（AS-Ⅳ）是中药黄芪的主要有效成分，在心血管疾病中具有突出作用，其可保护心肌细胞免受缺血缺氧性损伤，且具有抗炎、增强心肌收缩力、改善心肌舒张功能、减轻血管内皮功能障碍、促进血管新生等保护心脏结构及增强心脏功能的作用。心力衰竭患者心肌处于缺血缺氧状态，而AS-Ⅳ能减轻缺血缺氧并发挥心脏保护作用。本文通过分析相关文献发现，心力衰竭患者发生缺血缺氧性心肌损伤的机制包括离子失衡、氧化应激、线粒体能量代谢异常及血管生成障碍，而AS-Ⅳ可能通过调节离子平衡、减轻氧化应激、改善线粒体功能、促进血管生成来保护心力衰竭患者心肌细胞免受缺血缺氧性损伤。【关键词】心力衰竭；缺血缺氧性心肌损伤；黄芪甲苷；综述【中图分类号】R541.62【文献标识码】ADOI：10.12114/j.issn.1008-5971.2023.00.180ResearchProgressontheMechanismofAstragalosideⅣinPreventingIschemiaHypoxiaMyocardialInjuryinPatientswithHeartFailureGUANJing1,HUANGFanke1,ZHOUYilu1,LIBingqing1,CHENYuwen1,WANGYue1,SUNPeiyuan1,LYUJianfeng21.InstituteofCardiovascularandCerebrovascularDiseases,ChinaThreeGorgesUniversity,Yichang443000,China2.InternalMedicine-CardiovascularDepartment,AffiliatedRenheHospitalofChinaThreeGorgesUniversity,Yichang443000,ChinaCorrespondingauthor:LYUJianfeng,E-mail:ljfzxm@163.com【Abstract】AstragalosideⅣ(AS-Ⅳ)isthemaineffectivecomponentofastragalusmembranaceus,whichplaysaprominentroleincardiovasculardiseases.Itcanprotectmyocardialcellsfromischemiaandhypoxiainjury,andhasanti-inflammatory,enhancingmyocardialcontractility,improvingmyocardialdiastolicfunction,reducingvascularendothelialdysfunction,promotingangiogenesisandotherfunctionstoprotecttheheartstructureandenhancetheheartfunction.Inpatientswithheartfailure,themyocardiumisinastateofischemiaandhypoxia,whileAS-Ⅳcanalleviateischemiaandhypoxiaandplayacardiacprotectiverole.Basedontheanalysisofrelevantliterature,itisfoundthatthemechanismsofischemicandanoxi...
